Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Résumé : New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.
Type de document :
Article dans une revue
Lancet, Elsevier, 2015, 386 (9993), pp.552-61
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-01558410
Contributeur : Ghislaine Calvez <>
Soumis le : vendredi 7 juillet 2017 - 16:05:16
Dernière modification le : mercredi 29 novembre 2017 - 16:47:20

Identifiants

  • HAL Id : hal-01558410, version 1
  • PUBMED : 26051365

Collections

Citation

Hervé Bachelez, Peter C M Van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, et al.. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.. Lancet, Elsevier, 2015, 386 (9993), pp.552-61. 〈hal-01558410〉

Partager

Métriques

Consultations de la notice

34